Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Autolus Therapeutics (AUTL) Consolidated Net Income: 2016-2024

Historic Consolidated Net Income for Autolus Therapeutics (AUTL) over the last 9 years, with Dec 2024 value amounting to -$220.7 million.

  • Autolus Therapeutics' Consolidated Net Income rose 3.63% to -$79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.8 million, marking a year-over-year increase of 16.81%. This contributed to the annual value of -$220.7 million for FY2024, which is 5.89% down from last year.
  • Autolus Therapeutics' Consolidated Net Income amounted to -$220.7 million in FY2024, which was down 5.89% from -$208.4 million recorded in FY2023.
  • Over the past 5 years, Autolus Therapeutics' Consolidated Net Income peaked at -$142.1 million during FY2021, and registered a low of -$220.7 million during FY2024.
  • Moreover, its 3-year median value for Consolidated Net Income was -$208.4 million (2023), whereas its average is -$192.6 million.
  • As far as peak fluctuations go, Autolus Therapeutics' Consolidated Net Income climbed by 24.91% in 2021, and later plummeted by 39.98% in 2023.
  • Autolus Therapeutics' Consolidated Net Income (Yearly) stood at -$189.3 million in 2020, then increased by 24.91% to -$142.1 million in 2021, then declined by 4.73% to -$148.9 million in 2022, then tumbled by 39.98% to -$208.4 million in 2023, then declined by 5.89% to -$220.7 million in 2024.